Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
16 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/16/3206178/0/en/Elicio-Therapeutics-Reports-Inducement-Grants.html
19 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/19/3190855/0/en/Elicio-Therapeutics-Appoints-Veteran-CMC-and-Technical-Operations-Executive-Marc-J-Wolfgang-as-Chief-Technology-Officer.html
13 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/13/3187803/0/en/Elicio-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Updates.html
07 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/07/3183698/0/en/Elicio-Therapeutics-Reports-Robust-Cytolytic-mKRAS-Specific-T-Cell-Responses-Across-Diverse-Patient-HLA-in-Ongoing-Phase-2-AMPLIFY-7P-Trial-of-ELI-002-7P-and-New-ELI-004-Preclinica.html
03 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/03/3179208/0/en/Elicio-Therapeutics-to-Present-Clinical-and-Preclinical-Data-at-the-SITC-2025-Annual-Meeting.html
27 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/27/3174537/0/en/Elicio-Therapeutics-Reports-Robust-T-cell-Responses-Across-Diverse-HLA-backgrounds-in-Ongoing-Phase-2-AMPLIFY-7P-Trial.html
Drugs in Development
Details:
The Company intends to use the net proceeds for the development of ELI-002 7P (7-peptide formulation) in a Phase 1/2 trial in patients with mKRAS-driven pancreatic cancer.
Lead Product(s): ELI-002 7P
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: GKCC
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 04, 2025
Lead Product(s) : ELI-002 7P
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : GKCC
Deal Size : $10.0 million
Deal Type : Financing
Elicio Therapeutics Secures $10 Million in Financing
Details : The Company intends to use the net proceeds for the development of ELI-002 7P (7-peptide formulation) in a Phase 1/2 trial in patients with mKRAS-driven pancreatic cancer.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 04, 2025
Details:
ELI-002 7P is an investigational therapeutic cancer vaccine developed with Elicio’s proprietary AMP technology. It is being evauated for the treatment of KRAS mutated pancreatic ductal adenocarcinoma.
Lead Product(s): ELI-002 7P
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 22, 2025
Lead Product(s) : ELI-002 7P
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Details : ELI-002 7P is an investigational therapeutic cancer vaccine developed with Elicio’s proprietary AMP technology. It is being evauated for the treatment of KRAS mutated pancreatic ductal adenocarcinoma.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 22, 2025
Details:
ELI-002 7P is an investigational therapeutic cancer vaccine developed with Elicio’s proprietary AMP technology. It is being evauated for the treatment of KRAS mutated pancreatic ductal adenocarcinoma.
Lead Product(s): ELI-002 7P
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 03, 2024
Lead Product(s) : ELI-002 7P
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
Details : ELI-002 7P is an investigational therapeutic cancer vaccine developed with Elicio’s proprietary AMP technology. It is being evauated for the treatment of KRAS mutated pancreatic ductal adenocarcinoma.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 03, 2024
Details:
The net proceeds will be used for the clinical development of ELI-002, which is being evaluated for the treatment of mKRAS Pancreatic Ductal Adenocarcinoma and colorectal cancer.
Lead Product(s): ELI-002
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: Jones
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering June 27, 2024
Lead Product(s) : ELI-002
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Jones
Deal Size : Undisclosed
Deal Type : Public Offering
Elicio Therapeutics Announces Proposed Public Offering
Details : The net proceeds will be used for the clinical development of ELI-002, which is being evaluated for the treatment of mKRAS Pancreatic Ductal Adenocarcinoma and colorectal cancer.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 27, 2024
Details:
ELI-002 7P is an investigational therapeutic cancer vaccine developed with Elicio’s proprietary AMP technology. It is being evauated for the treatment of KRAS mutated pancreatic ductal adenocarcinoma.
Lead Product(s): ELI-002 7P
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 27, 2024
Lead Product(s) : ELI-002 7P
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Elicio Reports Preliminary Disease-Free Survival from AMPLIFY-7P Phase 1a Study
Details : ELI-002 7P is an investigational therapeutic cancer vaccine developed with Elicio’s proprietary AMP technology. It is being evauated for the treatment of KRAS mutated pancreatic ductal adenocarcinoma.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 27, 2024
Details:
Elicio will use proceeds to advance its pipeline, including ELI-002, a cancer vaccine targeting common KRAS mutations in patients with mKRAS.
Lead Product(s): ELI-002
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 18, 2024
Lead Product(s) : ELI-002
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $6.0 million
Deal Type : Private Placement
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
Details : Elicio will use proceeds to advance its pipeline, including ELI-002, a cancer vaccine targeting common KRAS mutations in patients with mKRAS.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 18, 2024
Details:
ELI-002 7P is an investigational cancer vaccine developed with Elicio’s Amphiphile technology, under Phase 1/2 development for treating KRAS mutated pancreatic ductal adenocarcinoma.
Lead Product(s): ELI-002 7P
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 11, 2024
Lead Product(s) : ELI-002 7P
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Elicio Therapeutics Doses First Patient in Phase 2 Pancreatic Cancer Study
Details : ELI-002 7P is an investigational cancer vaccine developed with Elicio’s Amphiphile technology, under Phase 1/2 development for treating KRAS mutated pancreatic ductal adenocarcinoma.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 11, 2024
Details:
Elicio intends to use the net proceeds for the advancement of its development pipeline, including ELI-002, an investigational therapeutic cancer vaccine created with its proprietary lymph node-targeting Amphiphile (AMP) technology.
Lead Product(s): ELI-002
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: GKCC
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 22, 2023
Lead Product(s) : ELI-002
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : GKCC
Deal Size : $7.0 million
Deal Type : Private Placement
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
Details : Elicio intends to use the net proceeds for the advancement of its development pipeline, including ELI-002, an investigational therapeutic cancer vaccine created with its proprietary lymph node-targeting Amphiphile (AMP) technology.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 22, 2023
Details:
The funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations.
Lead Product(s): ELI-007
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Vaccine
Sponsor: GI Research Foundation
Deal Size: $5.4 million Upfront Cash: Undisclosed
Deal Type: Funding September 07, 2023
Lead Product(s) : ELI-007
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : GI Research Foundation
Deal Size : $5.4 million
Deal Type : Funding
Details : The funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
September 07, 2023
Details:
The combined company will focus on the advancement of its clinical development program, ELI-002, a therapeutic cancer vaccine designed with Elicio’s proprietary lymph node-targeting AMP technology, being evaluated in patients with mKRAS-driven solid tumors.
Lead Product(s): ELI-002 7P
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Recipient: Angion Biomedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 01, 2023
Lead Product(s) : ELI-002 7P
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Angion Biomedica
Deal Size : Undisclosed
Deal Type : Merger
Elicio Therapeutics Announces Completion of Merger with Angion Biomedica
Details : The combined company will focus on the advancement of its clinical development program, ELI-002, a therapeutic cancer vaccine designed with Elicio’s proprietary lymph node-targeting AMP technology, being evaluated in patients with mKRAS-driven solid tu...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 01, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
